GlassScriptPhysician profile
Steven J Eisenberg
NPI 1902849565
$24,394.90
in general payments reported to CMS, 2019-2025
33 companies · $1,284 in 2025
The $1,284 reported for 2025 was more than what 76% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $1,638 · 2021: $1,463 · 2022: $1,395 · 2023: $1,569 · 2024: $1,493 · 2025: $1,284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,345.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $5,834.22 | 2019-2025 | Jardiance |
| Amgen INC. | $5,477.30 | 2019-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $2,927.06 | 2019-2025 | Watchman Flx, Watchman Access System, Bodyguardian |
| Edwards Lifesciences Corporation | $1,867.20 | 2019-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| E.R. Squibb & Sons, L.L.C. | $1,751.60 | 2019-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $1,202.73 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $949.94 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $623.83 | 2020-2025 | Farxiga |
| Pfizer INC. | $588.10 | 2019-2025 | |
| Amarin Pharma, INC. | $450.17 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $340.52 | 2021-2024 | Verquvo |
| Atricure, INC. | $311.41 | 2023-2025 | Synergy Ablation System, Epi-Sense Guided Coagulation System With Visitrax, Atriclip Laa Exclusion System |
| Astellas Pharma US INC | $291.40 | 2019-2021 | |
| Esperion Therapeutics, INC. | $284.32 | 2021-2025 | Nexletol |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $274.31 | 2019-2024 | Lifevest |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $183.94 | 2022-2025 | Ffrct |
| Sanofi-Aventis U.S. LLC | $160.34 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $140.87 | 2019-2024 | Evkeeza, Praluent |
| Kowa Pharmaceuticals America, INC. | $129.15 | 2019-2021 | |
| Abiomed | $118.58 | 2024-2025 | Impella |
| Vital Connect, INC | $113.56 | 2024-2025 | Vitalpatch Rtm |
| Abbott Laboratories | $87.11 | 2021-2024 | Mitraclip |
| Novo Nordisk INC | $61.53 | 2025 | Wegovy |
| Kiniksa Pharmaceuticals, LTD. | $49.74 | 2021-2023 | Arcalyst |
| Bardy Diagnostics, INC. | $29.00 | 2019-2020 | |
| Chiesi USA, INC. | $25.68 | 2025 | Juxtapid |
| Exelixis INC. | $21.49 | 2024 | Cabometyx |
| Kestra Medical Technology Services, INC. | $20.07 | 2022 | |
| Lilly USA, LLC | $19.33 | 2025 | Mounjaro |
| Kiniksa Pharmaceuticals International, Plc | $18.09 | 2024 | Arcalyst |
| Emd Serono, INC. | $17.24 | 2019 | |
| Medicure Pharma INC. | $13.96 | 2019 | |
| Medicomp INC | $11.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Eisenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.